2seventy bio Inc

+0.39 (+3.43%)
Products, Other Pre-Announcement

2Seventy Bio Reports Fourth Quarter And Full Year 2021 Financial Results

Published: 03/22/2022 11:19 GMT
2seventy bio Inc (TSVT) - 2seventy Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress.
Q4 Revenue $67 Million.
Cash Runway Into 2025.
Internal Cost Reduction Measures Reduce Net Cash Spend Guidance to $190-$220 Million for 2022.
Qtrly Net Loss per Share $(2.55).
Tracking Toward Upper End of $250-$300 Million U.S. Revenue Guidance for 2022 for Abecma.
2seventy Bio - Continue to Anticipate Abecma Will Be Sustainably Cash Flow Positive for Co, Inclusive of Research and Development Costs, by End of 2022.
Q4 Earnings per Share View $-2.84 -- Refinitiv Ibes Data (analyst estimates).